drug · protein
povetacicept
Phase 3updated 6mo agoby $VERX Vertex, Inc.🔗 ChEMBL
Phase 3community read0 votes
Protein drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
all catalysts(0)
nothing on the calendar yet
Trials studying povetacicept
- phase3Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
- phase3A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy
- phase2A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
- phase3Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
- phase2An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
- phase1A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations
- phase2An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
News(10)
- Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked NovemberNovartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about th…biospace · 6d ago
- Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked NovemberAlso lined up are target action dates for Sanofi’s Gaucher disease therapy, GSK’s lung cancer medicine and BridgeBio’s muscular dystrophy drug.biospace · 10d ago
- Vertex, ahead of FDA decision, calms fears surrounding kidney drugOn a conference call, executives expressed conviction in the coming launch of an IgA nephropathy medicine viewed by Wall Street investors as important to Vertex’s future.biopharma_dive · 13d ago
- Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s assetJapan’s Ono Pharmaceutical is paying $80 million upfront for the regional rights to a trio of Biohaven’s IgG degraders, led by a phase 3-stage Grave’s disease prospect.fiercebiotech · 1mo ago
- Vertex opens up larger kidney disease opportunity with mid-stage readoutWhile Vertex is laser-focused on an upcoming FDA decision for povetacicept in immunoglobulin A nephropathy, the APOL1 inhibitor inaxaplin has demonstrated potential “best-in-class” data in a differ…biospace · 1mo ago
- Frazier adds $1.1B+ to small and mid-sized biotech fundFrazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for…biospace · 2mo ago
- Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsBoulevard Bio has strolled out of stealth with $65 million in funding from Deerfield Management and three autoimmune disease candidates.fiercebiotech · 3mo ago
- Vertex unfazed by competitive IgAN space as FDA verdict loomsPositive two-year follow-up data for Otsuka Pharmaceuticals’ IgA nephropathy drug Voyxact could support the FDA’s ongoing review of Vertex Pharmaceuticals’ povetacicept, CEO Reshma Kewalramani said…biospace · 3mo ago
- Vertex’s IgA nephropathy drug derisked after Novartis, Vera approvalsThe FDA is currently reviewing Vertex Pharmaceuticals’ povetacicept, with a target action date of Nov. 30. If approved, the drug could benefit from campaigns from Novartis and Vera Therapeutics for…biospace · 4mo ago
- 10 clinical trials to watch in the second half of 2026The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.biopharma_dive · 4mo ago
Data sources
last refreshed 5h ago
Found something off?
comments(0)
5-min edit window · permanent after that